We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Effective July 1, 2012, pursuant to provisions in the Massachusetts FY 2013 Appropriations Act (the state budget), pharmaceutical and medical device manufacturers (“Manufacturers”) will now be able to provide or pay for “modest meals and refreshments” for health care practitioners in connection with certain non-CME educational presentations
In furtherance of the Transparency Initiative launched in 2009, the FDA published its first ever guidance document on benefit-risk analysis for medical devices
On February 9, 2012, the U.S. Food and Drug Administration (FDA) issued three draft guidance documents the first since the Biologics Price Competition and Innovation Act passed in March 2010 for the development of biosimilars
On June 23, 2011, the Supreme Court in Sorrell, Attorney General of Vermont, et al. v. IMS Health Inc. et al, struck down a Vermont law that bans the sale of physicians’ prescribing information to pharmaceutical companies and further bans pharmaceutical companies from using such data to market their products
